• 1
    Luo JC, Chang FY, Lin HY, Lu RH, Lu CL, Chen CY, Lu RH, Lee SD. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther 2002; 16: 12418.
  • 2
    Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 4739.
  • 3
    Messer J, Reitman D, Sacks HS, Smith H Jr , Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 214.
  • 4
    Hernandez-Diaz S, Rodriguez LAG. Steroid and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153: 108993.
  • 5
    Bandyopadhyay U, Biswas K, Bandyopadhyay D, Ganguly CK, Banerjee RK. Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase – two important gastroprotective enzymes. Mol Cell Biochem 1999; 202: 316.
  • 6
    Okazaki K, Chiba T, Hajiro K. Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human. J Clin Gastroenterol 1998; 27 (Suppl. 1): S916.
  • 7
    Luo JC, Shin VY, Liu ESL, So WHL, Ye YN, Chang FY, Cho CH. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther 2003; 307: 6928.
  • 8
    Luo JC, Shin VY, Liu ESL, Ye YN, Wu WKK, So WHL, Chang FY, Cho CH. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 2004; 485: 27581.
  • 9
    Hawkey CJ. Nonsteroidal anti-inflammatory drugs gastropathy. Gastroenterology 2000; 119: 52135.
  • 10
    Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 70614.
  • 11
    Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 43S53S.
  • 12
    Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001; 132: 156573.
  • 13
    Badsha H, Edwards CJ. Intravenous pulse of methylprednisolone for systemic lupus erythematous. Semin Arthritis Rheum 2003; 32: 3707.
  • 14
    Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 6198.
  • 15
    Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron C, Launay D, Morell-Dubois S, Queyrel V, Hatron PY. Influence of aspirin on the clinical outcome of 103 anti-phospholipid antibodies-positive patients. Lupus 2008; 17: 115.
  • 16
    Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematous with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 2936.
  • 17
    Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
  • 18
    Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 1725.
  • 19
    Lanza F, Royer GL, Nelson RS, Chen TT, Seckman CE, Rack MF. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981; 75: 1721.
  • 20
    Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001; 120: 86773.
  • 21
    Wallace JL. Glucocorticoid-induced gastric mucosal damage: inhibition of leukotriene, but not prostaglandin biosynthesis. Prostaglandins 1987; 34: 31123.
  • 22
    Treiber G, Wex T, Link A, Vieth M, Laufer S, Malfertheiner P. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Aliment Pharmacol Ther 2006; 23: 15567.
  • 23
    Tornatore KM, Reed KA, Venuto RC. Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. Ann Pharmacol 1995; 29: 1204.
  • 24
    Weusten BLMA, Jacobs JWG, Bijlsma JWJ. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 18392.
  • 25
    Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticoid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 73540.
  • 26
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 1422.
  • 27
    Graham DY, Smith JL, Spjut HJ, Torres E. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology 1988; 85: 32733.